Meeting
2017 ASCO Annual Meeting
A randomized, double-blind phase III study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease.
Authors
David Bernard Miklos
Stanford University Medical Center, Stanford, CA
David Bernard Miklos , Madan H. Jagasia , Hildegard Greinix , Bor-Sheng Ko , David A. Jacobsohn , Ahmad Mokatrin , Jason Dubovsky , Biljana Horn , Bernhard Hauns , Lori Appel Styles , Mary Flowers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogenic Stem Cell Transplantation
Clinical Trial Registration Number
NCT02959944
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS7072)
DOI
10.1200/JCO.2017.35.15_suppl.TPS7072
Abstract #
TPS7072
Poster Bd #
269a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).
First Author: Ariela Noy
Poster
2021 ASCO Annual Meeting
ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
First Author: Laurie Helen Sehn
Poster
2023 ASCO Annual Meeting
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
First Author: Mark Andrew Dickson
Poster
2017 ASCO Annual Meeting
Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).
First Author: Charalambos Andreadis